Earnings
|
Reports Q4 revenue $7.8M,… Reports Q4 revenue $7.8M, consensus $7.96M. "We made considerable progress across the business during 2020, including building strong demand for our products. Total product sales increased by 119%, including 284% in the U.S. market. We sold 57 new T2Dx Instruments, including 47 in the U.S., which more than doubled our U.S. instrument installed base, and increased sepsis test utilization in the U.S. by 72% compared to the prior year," stated John Sperzel, President and CEO of T2 Biosystems. "Heading into 2021, we will continue to focus on three corporate priorities - accelerating our commercialization, improving our operations, and advancing our product pipeline - which we believe positions the company for sustained growth and long-term success." ShowHide Related Items >><< - 02/04/21
- T2 Biosystems T2SARS-CoV can detect Brazil P.1 variant SARS-CoV 2 virus
- 01/11/21
- T2 Biosystems: T2SARS-CoV-2 Panel can detect multiple variants of COVID-19
- 01/07/21
- T2 Biosystems appoints Aparna Ahuja as CMO
- 10/19/20
- Sepsis Alliance elects T2 Biosystems CEO as board member
- 01/27/21 Alliance Global Partners
- T2 Biosystems downgraded to Neutral from Buy at Alliance Global Partners
- 11/05/20 Alliance Global Partners
- T2 Biosystems price target raised to $2.60 from $1.65 at Alliance Global
- 10/07/20 BTIG
- T2 Biosystems initiated with a Buy at BTIG
- 09/30/20 JonesTrading
- JonesTrading reiterates $3.50 target on T2 Biosystems after BARDA contract
- 01/26/21
- T2 Biosystems sees FY20 revenue $18.1M, consensus $19.32M
- 01/26/21
- T2 Biosystems sees Q4 revenue $7.8M, consensus $9.01M
- 02/05/21
- Fly Intel: Wall Street's top stories at midday
- 01/26/21
- Fly Intel: After-Hours Movers
- 01/12/21
- Fly Intel: Pre-market Movers
- 03/04/21
- T2 Biosystems options imply 26.4% move in share price post-earnings
- 02/10/21
- Largest borrow rate increases among liquid names
- 01/12/21
- Unusually active option classes on open January 12th
- 10/06/20
- Largest borrow rate increases among liquid names
|
Conference/Events
|
MedTech, Digital Health,… MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference will be held on February 17-19. Webcast Link ShowHide Related Items >><< - 11/17/20
- Intersect ENT announces new leadership appointments
- 09/15/20
- Intersect ENT agrees to acquire Fiagon AG Medical Technologies for EUR 60M
- 09/15/20
- Intersect ENT agrees to acquire Fiagon AG Medical Technologies for EUR 60M
- 09/10/20
- Intersect ENT signs Sinuva distribution agreement with AllianceRx Walgreens
- 02/12/21
- Vapotherm's HVT2.0 added to FDA's ventilator accessories EUA
- 11/09/20
- Vapotherm falls -24.0%
- 02/04/21
- T2 Biosystems T2SARS-CoV can detect Brazil P.1 variant SARS-CoV 2 virus
- 01/11/21
- T2 Biosystems: T2SARS-CoV-2 Panel can detect multiple variants of COVID-19
- 01/07/21
- T2 Biosystems appoints Aparna Ahuja as CMO
- 10/19/20
- Sepsis Alliance elects T2 Biosystems CEO as board member
- 01/05/21
- Tela Bio appoints Bruce Freedman as VP, clinical development
- 09/25/20
- Tela Bio presents additional data from BRAVO study of OviTex
- 08/26/20
- Stereotaxis announces publication on study using robotic technology
- 02/02/21
- Simulations Plus enters agreement with distributor in China
- 01/26/21
- Simulations Plus enters distribution agreement with ICF
- 01/12/21
- Simulations Plus in funded pact to enhance PBPK/PD approaches
- 12/01/20
- Simulations Plus names Will Frederick CFO
- 12/22/20
- Quotient COO Ed Farrell to resign
- 12/10/20
- Quotient receives FDA request for testing data on Initial SDS Microarray, MosaiQ
- 09/28/20
- Quotient announces receipt of FDA EUA for MosaiQ COVID-19 antibody test
- 09/08/20
- Quotient, Ortho Clinical Diagnostics settle arbitration
- 02/17/21
- Natera, Personalis partner for personalized oncology monitoring
- 12/09/20
- Personalis announces 100,000th genome delivery to VA
- 09/17/20
- Personalis receives contract extension, new task order from VA
- 02/17/21
- Progenity initiates safety, tolerability srudy of Drug Delivery System capsule
- 02/12/21
- Progenity 'applauds' SMFM focus on preeclampsia biomarkers
- 01/20/21
- Progenity reaches 2M test milestone
- 01/05/21
- Progenity Inc trading resumes
- 02/11/21
- Orthofix announces U.S., European market launch of Fitbone lengthening system
- 01/28/21
- Orthofix publishes data from the M6-C artificial cervical disc study
- 10/01/20
- Orthofix receives additional FDA clearance for nanotechnology
- 09/22/20
- Orthofix, Neo Medical in pact to develop, market single-use spinal solutions
- 01/25/21
- Inari Medical to present chronic clot subanalysis results
- 01/08/21
- Inari Medical's FlowTriever system receives 510(k) clearance
- 11/13/20
- Inari Medical presents 30-day follow-up results from FLASH study
- 10/19/20
- Inari Medical announces presentation of results from real world FLASH registry
- 02/18/21
- Myriad Genetics promotes Kevin Haas to CTO
- 02/12/21
- Myriad Genetics announces additional data on Prolaris test
- 02/09/21
- ASCO abstract says Myriad Genetics' CCR 'adds clinically actionable information'
- 02/08/21
- Myriad Genetics' GeneSight Psychotropic test shows superior prediction efficacy
- 01/11/21
- MediWound reduces EscharEx Phase 2 adaptive design study to 120 patients
- 12/21/20
- MediWound completes in-vivo head-to-head comparator study of EscharEx
- 12/14/20
- MediWound expands NexoBrid global presence in UAE with Ghassan Aboud
- 10/28/20
- MediWound completes enrollment for NexoBrid Phase 3 pediatric study
- 02/18/21
- OrthoPediatrics launches dedicated ApiFix website
- 01/22/21
- OrthoPediatrics introduces Orthex in Australia
- 01/15/21
- OrthoPediatrics expands agent network in Germany, Austria, Switzerland
- 01/05/21
- OrthoPediatrics launches sterile implants for PNP FEMUR system
- 12/29/20
- iCAD to partner with Dr. Santosh Kesari evaluating its eBx system to treat GBM
- 12/10/20
- Solis Mammography adopts iCAD's ProFound AI platform
- 11/30/20
- iCAD highlights suite of breast health AI solutions at RSNA 2020
- 11/25/20
- iCAD announces data on treatment of early-stage breast, gynelogical cancers
- $187.56 /
-13.67 (-6.79%) - 01/13/21
- Heska to acquire Lacuna Diagnostics, terms not disclosed
- 01/11/21
- HealthEquity expects 5.7M-5.8M HSA members by Jan. 31
- 02/15/21
- Fly Intel: Top five weekend stock stories
- 02/01/21
- Hologic, Google Cloud collaborate over digital diagnostic capabilities
- 01/08/21
- Hologic announces new, five-year $1B share repurchase plan
- 01/05/21
- Hologic to acquire Biotheranostics for about $230M
- 02/10/21
- Fluidigm says longitudinal study of SARS-CoV-2 patients to utilize Maxpar Direct
- 02/10/21
- Fluidigm announces supply agreement with PuLuoTing Health for CyTOF technology
- 02/09/21
- Fluidigm's mass cytometry technology to be used in pediatric COVID-19 study
- 01/26/21
- Fluidigm partners with Helix Specialty Diagnostics for COVID-19 testing
- 02/11/21
- CareDx announces exercise of underwriters option to purchase additional shares
- 01/08/21
- CareDx to acquire TransChart, terms not disclosed
- 01/07/21
- CareDx announces exclusive partnership with IDbyDNA
- 01/04/21
- CareDx's AlloSeq HCT wins tender for stem cell transplant surveillance
- 02/11/21
- Bionano Genomics announces publication on method for optical genome mapping
- 02/09/21
- Bionano Genomics' Saphyr adopted by Canada's largest hospital diagnostic lab
- 02/02/21
- Bionano Genomics announces publication of study on DNA methylation
- 01/29/21
- Bionano Genomics announces presentation on optical genome mapping
- 01/29/21
- Abiomed announces study finds 79% survival rate at explant for Impella 5.5
- 01/07/21
- Abiomed surpasses more than 1,000 patents worldwide
- 12/21/20
- Abiomed says first two patients treated with Abiomed Breethe OXY-1 System
- 12/15/20
- Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath
- 01/28/21 Piper Sandler
- Abiomed price target raised to $425 from $350 at Piper Sandler
- 12/21/20 SVB Leerink
- Abiomed price target raised to $320 from $280 at SVB Leerink
- 12/14/20 Piper Sandler
- Abiomed gets approval for XR sheath, says Piper Sandler
- 10/20/20 Piper Sandler
- Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
- 02/08/21 Oppenheimer
- Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
- 01/26/21 Ladenburg
- Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
- 01/22/21 Maxim
- Bionano Genomics price target raised to $14 from $2 at Maxim
- 12/04/20 Roth Capital
- Bionano Genomics downgraded to Neutral from Buy at Roth Capital
- 01/12/21 Piper Sandler
- CareDx price target raised to $93 from $62 at Piper Sandler
- 01/04/21 Craig-Hallum
- CareDx price target raised to $94 from $66 at Craig-Hallum
- 12/17/20 BTIG
- CareDx price target raised to $80 from $55 at BTIG
- 12/10/20 Raymond James
- CareDx price target raised to $75 from $62 at Raymond James
- 12/14/20 Lake Street
- Medavail initiated with a Buy at Lake Street
- 12/14/20 Cowen
- Medavail initiated with an Outperform at Cowen
- 10/19/20 Stifel
- Orthofix initiated with a Hold at Stifel
- 02/25/20 Cantor Fitzgerald
- Orthofix price target lowered to $42 from $48 at Cantor Fitzgerald
- 01/15/21 Piper Sandler
- Vapotherm price target raised to $39 from $36 at Piper Sandler
- 01/13/21 Piper Sandler
- Vapotherm remains top small pick at Piper Sandler
- 12/17/20
- Fly Intel: Top five analyst initiations
- 12/17/20 Piper Sandler
- Vapotherm initiated with an Overweight at Piper Sandler
- 01/14/21 Piper Sandler
- Piper says Tela Bio momentum looks 'healthy' despite 'slight' Q4 miss
- 11/11/20 Piper Sandler
- Tela Bio price target raised to $20 from $17 at Piper Sandler
- 08/12/20 Piper Sandler
- Tela Bio price target raised to $17 from $14 at Piper Sandler
- 07/09/20 Piper Sandler
- Piper recommends buying Tela Bio shares after 'strong' OviTex data
- 01/25/21 BTIG
- Tactile Systems price target raised to $60 from $51 at BTIG
- 11/13/20 Oppenheimer
- Tactile Systems upgraded to Outperform from Perform at Oppenheimer
- 11/13/20 Oppenheimer
- Tactile Systems upgraded to Outperform from Perform at Oppenheimer
- 11/03/20 Piper Sandler
- Tactile Systems shares still recommended after results at Piper Sandler
- 01/27/21 Alliance Global Partners
- T2 Biosystems downgraded to Neutral from Buy at Alliance Global Partners
- 11/05/20 Alliance Global Partners
- T2 Biosystems price target raised to $2.60 from $1.65 at Alliance Global
- 10/07/20 BTIG
- T2 Biosystems initiated with a Buy at BTIG
- 09/30/20 JonesTrading
- JonesTrading reiterates $3.50 target on T2 Biosystems after BARDA contract
- 09/08/20 Northland
- Stereotaxis initiated with an Outperform at Northland
- 06/22/20 Lake Street
- Stereotaxis price target raised to $9 from $5 at Lake Street
- 05/27/20 Lake Street
- Stereotaxis financing, addition of Consonance both positive, says Lake Street
- 04/09/20 Cowen
- Stereotaxis initiated with an Outperform at Cowen
- 02/08/21 Wells Fargo
- Progenity downgraded to Underweight from Overweight at Wells Fargo
- 01/14/21 Piper Sandler
- Progenity price target lowered to $10 from $15 at Piper Sandler
- 12/08/20 Piper Sandler
- Progenity shares not trading on fundamentals, says Piper Sandler
- 11/10/20 Piper Sandler
- Progenity price target lowered to $15 from $17 at Piper Sandler
- 05/18/20 Cowen
- Quotient partner update suggests progress on antibody front, says Cowen
- 01/12/21
- Fly Intel: Top five analyst downgrades
- 01/12/21 Craig-Hallum
- Simulations Plus downgraded to Hold from Buy at Craig-Hallum
- 01/12/21 Oppenheimer
- Simulations Plus price target raised to $85 from $79 at Oppenheimer
- 11/25/20 Taglich Brothers
- Simulations Plus upgraded to Buy from Speculative Buy at Taglich Brothers
- 11/10/20 Piper Sandler
- Myriad Genetics price target raised to $18 from $14 at Piper Sandler
- 08/17/20 Piper Sandler
- ACOG recommendation 'extremely' positive for Natera and Progenity, says Piper
- 06/11/20 Piper Sandler
- Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
- 05/06/20 JPMorgan
- Myriad Genetics price target lowered to $12 from $14 at JPMorgan
- 01/21/21 BTIG
- Inari Medical price target raised to $110 from $92 at BTIG
- 01/20/21 Wells Fargo
- Inari Medical price target raised to $112 from $79 at Wells Fargo
- 12/15/20 Wells Fargo
- Wells Fargo says Buy Inari Medical, Sell NuVasive in MedTech ratings shake-up
- 12/15/20 Wells Fargo
- Inari Medical upgraded to Overweight from Equal Weight at Wells Fargo
- 01/15/21 Piper Sandler
- Intersect ENT price target raised to $23 from $17 at Piper Sandler
- 01/11/21 Canaccord
- Intersect ENT upgraded to Buy from Hold at Canaccord
- 11/19/20 BTIG
- Intersect ENT upgraded to Buy from Neutral at BTIG
- 11/02/20 Piper Sandler
- Intersect ENT price target raised to $17 from $16 at Piper Sandler
- 01/28/21 Wells Fargo
- Hologic price target raised to $95 from $90 at Wells Fargo
- 12/08/20 Argus
- Hologic price target raised to $100 from $85 at Argus
- 11/20/20
- Fly Intel: Top five analyst downgrades
- 11/20/20 Needham
- Needham downgrades Hologic ahead of COVID-19 testing decline
- 01/28/21 Cantor Fitzgerald
- Cantor Fitzgerald starts iCAD at Overweight with $19 price target
- 01/28/21 Cantor Fitzgerald
- iCAD initiated with an Overweight at Cantor Fitzgerald
- 12/15/20 B. Riley
- iCAD price target raised to $18 from $15 at B. Riley Securities
- 12/11/20 Lake Street
- iCAD price target raised to $17 from $14 at Lake Street
- $187.56 /
-13.67 (-6.79%) - 01/29/21 JPMorgan
- Heska initiated with an Overweight at JPMorgan
- 11/23/20 Piper Sandler
- Heska price target raised to $157 from $150 at Piper Sandler
- 11/04/20 Alliance Global Partners
- Heska price target raised to $163.50 from $116.50 at Alliance Global Partners
- 10/21/20 Raymond James
- Heska upgraded to Outperform from Market Perform at Raymond James
- 02/10/21 Raymond James
- HealthEquity price target raised to $100 from $75 at Raymond James
- 02/09/21 Barrington
- HealthEquity price target raised to $90 from $75 at Barrington
- 02/09/21 Truist
- HealthEquity price target raised to $92 from $80 at Truist
- 02/09/21 RBC Capital
- HealthEquity price target raised to $87 from $74 at RBC Capital
- 02/11/21 Piper Sandler
- Fluidigm price target lowered to $8 from $15 at Piper Sandler
- 12/17/20 BTIG
- Illumina upgraded to Buy from Neutral at BTIG
- 11/09/20 Piper Sandler
- Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
- 10/19/20 Piper Sandler
- Fluidigm test pact in Texas 'another validation,' says Piper Sandler
- 10/19/20 BTIG
- Vericel price target raised to $30 from $23 at BTIG
- 09/23/20
- Fly Intel: Top five analyst initiations
- 09/23/20 BTIG
- MediWound initiated with a Buy at BTIG
- 12/03/20 Stifel
- Stifel says short report claims about OrthoPediatrics 'overstated,' 'inaccurate'
- 10/07/20 BTIG
- OrthoPediatrics price target raised to $57 from $54 at BTIG
- 08/06/20 Piper Sandler
- Piper says OrthoPediatrics can win in 'more muted competitive environment'
- 08/06/20 Needham
- OrthoPediatrics price target raised to $57 from $49 at Needham
- 01/27/21 Truist
- Personalis initiated with a Buy at Truist
- 01/04/21 BofA
- Personalis downgraded to Neutral on valuation at BofA
- 01/04/21 BofA
- Personalis downgraded to Neutral from Buy at BofA
- 12/17/20 BTIG
- BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks'
- 01/12/21
- Intersect ENT reports preliminary Q4 revenue $27.7M-$28.1M, consensus $27.67M
- 11/02/20
- Intersect ENT reports Q3 EPS (35c), consensus (45c)
- 10/15/20
- Intersect ENT sees Q4 revenue about 85%-90% of Q4 in FY19
- 10/15/20
- Intersect ENT sees Q3 revenue $22.4M-$22.8M, consensus $21.4M
- 01/13/21
- Vapotherm sees FY20 revenue approximately $125.4M, consensus $117.06M
- 01/13/21
- Vapotherm sees Q4 revenue approximately $40.6M, consensus $32.25M
- 12/01/20
- Vapotherm raises FY20 revenue view to $114.8M-$117.8M, consensus $103.91M
- 12/01/20
- Vapotherm raises Q4 revenue view to $30M-$33M from $18M-$20M
- 01/26/21
- T2 Biosystems sees FY20 revenue $18.1M, consensus $19.32M
- 01/26/21
- T2 Biosystems sees Q4 revenue $7.8M, consensus $9.01M
- 01/14/21
- Tela Bio sees 2020 revenue $18M-$18.2M, consensus $18.55M
- 01/14/21
- Tela Bio sees Q4 revenue $5.5M-$5.7M, consensus $6.01M
- 11/11/20
- Tela Bio reports Q3 EPS (53c), consensus (49c)
- 11/09/20
- Stereotaxis sees double-digit revenue growth in 2021, consensus 37.23M
- 11/09/20
- Stereotaxis reports Q3 EPS (3c), consensus (3c)
- 01/11/21
- Simulations Plus reports Q1 EPS 12c, consensus 11c
- 11/16/20
- Simulations Plus reports Q4 EPS 11c, consensus 9c
- 02/01/21
- Quotient sees FY21 total product sales of Alba by Quotient $33.5M-$34M
- 02/01/21
- Quotient sees Q4 Alba by Quotient product sales $8.3M-$8.8M
- 02/01/21
- Quotient reports Q3 EPS (29c), consensus (29c)
- 11/02/20
- Quotient sees FY21 revenue $32M-$34M, consensus $34.86M
- 01/11/21
- Personalis reports preliminary Q4 revenue $20.2M, consensus $19.7M
- 11/05/20
- Personalis not providing FY20 guidance
- 11/05/20
- Personalis reports Q3 EPS (27c), consensus (28c)
- 10/29/20
- Progenity sees Q3 revenue $25M-$26M, consensus $34.74M
- 01/12/21
- Orthofix sees Q4 revenue $118M, consensus $109.77M
- 11/05/20
- Orthofix reports Q3 adj. EPS 31c vs. 41c last year
- 01/13/21
- Inari Medical sees Q4 revenue $47.9M-$48.9M, consensus $38.5M
- 11/12/20
- Inari Medical reports Q3 EPS 12c, consensus (4c)
- 11/09/20
- Myriad Genetics not providing financial guidance
- 11/09/20
- Myriad Genetics reports Q3 adj. EPS (15c), consensus (30c)
- 11/10/20
- MediWound reports Q3 EPS (7c), consensus (10c)
- 01/11/21
- OrthoPediatrics reports preliminary Q4 revenue $21.7M, consensus $20.31M
- 11/05/20
- iCAD reports Q3 EPS (7c), consensus (11c)
- 02/09/21
- HealthEquity raises FY21 EPS view to $1.67-$1.71 from $1.55-$1.61
- 02/09/21
- HealthEquity guides FY22 revenue $740M-$750M, consensus $767.8M
- 12/07/20
- HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58
- 12/07/20
- HealthEquity reports Q3 EPS 41c, consensus 36c
- 01/27/21
- Hologic sees Q2 adjusted EPS $2.56-$2.68, consensus $2.02
- 01/27/21
- Hologic reports Q1 adjusted EPS $2.86, consensus $2.17
- 01/27/21
- Notable companies reporting after market close
- 01/08/21
- Hologic reports preliminary Q1 revenue $1.61B, consensus $1.38B
- 02/10/21
- Fluidigm sees Q1 revenue $30M-$33M, consensus $47.62M
- 02/10/21
- Fluidigm reports Q4 EPS (13c), consensus (7c)
- 11/05/20
- Fluidigm reports Q3 EPS 3c, consensus (20c)
- 01/11/21
- CareDx reports preliminary 2020 revenue $191.9M-$192.1M, consensus $186.75M
- 01/11/21
- CareDx reports preliminary Q4 revenue $58.4M-$58.6M, consensus $53.21M
- 10/29/20
- CareDx reports Q3 EPS 10c, consensus (6c)
- 10/07/20
- CareDx sees Q3 revenue $53M, consensus $44.68M
- 11/12/20
- Bionano Genomics reports Q3 revenue $2.2M, consensus $2.07M.
- 10/15/20
- Bionano Genomics sees Q3 revenue $1.9M-$2.3M, consensus $2.07M
- 01/28/21
- Abiomed sees Q4 revenue $225M-$235M, consensus $230.96M
- 01/28/21
- Abiomed reports Q3 EPS $1.35, consensus $1.13
- 01/28/21
- Abiomed reports Q3 EPS $1.35, consensus $1.13
- 10/29/20
- Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M
|